factors affecting posology Options
However, You will find there's minority of conditions in which the therapy of EID utilizing the ICOC chelation protocol involving DF or L1 or their blend is probably not feasible as a consequence of minimal tolerability or harmful side effects including allergic reactions through parenteral infusion of DF or toxicity which include L1 agranulocytosi